REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?

Regeneron shares have rallied ~41% over the past six months to a 52-week high of $792.77 (Dec. 24, 2025) as pipeline and regulatory wins bolster investor sentiment. Key catalysts include FDA approval of Eylea HD 8 mg with expanded dosing options (Eylea HD U.S. sales +10% in Q3 2025), Libtayo generating $1.03 billion in sales in the first nine months of 2025 (+21% YoY), and ongoing Dupixent label expansions supporting revenue; the company also saw EU approvals for oncology assets and new product approvals (Lynozyfic, Ordspono). Valuation is rich at a 22.21x forward P/E versus a historical mean near 19x, and analyst estimates/momentum have been mixed, but Zacks currently ranks REGN a #2 (Buy).

Analysis

Market structure: Eylea HD lifts Regeneron (REGN) from pure vulnerability to Roche’s Vabysmo toward a two-horse retinal market where durability (dosing interval) now drives share and pricing power. Winners: REGN (Eylea HD adoption), Sanofi (Dupixent tailwinds), Bayer (ex‑US sales); Losers: incumbents with non-durable anti‑VEGF franchises and smaller ophthalmology developers. Expect slower per‑patient dollar growth but higher patient retention if Eylea HD secures ≥10–15% incremental share over 12 months; tighter IVs and lower equity volatility as headline risk subsides should compress options premia and CDS spreads modestly.

Risk assessment: Key tail risks include a Vabysmo superiority readout or payer rebasing that could trigger a >25% downside (plausible 10–20% probability in 12–24 months), regulatory setbacks to label expansions (5–10% near‑term risk), and partner revenue/royalty disputes. Immediate (days) risk is headline/news volatility around upcoming label or script share releases; short term (3–6 months) hinges on Q4/2025 sales cadence and physician uptake; long term (12–36 months) depends on oncology and obesity program readouts and biosimilar/patent expiries. Hidden dependencies: US vs ex‑US revenue recognition (Bayer split) and Sanofi royalties materially mute EPS leverage.

Trade implications: Establish a tactical 2–3% long REGN position on dips below $720 (retest of recent support) with a 12‑month target to retest $900 and stop‑loss at 15% downside. Pair trade: long REGN (2%) / short RHHBY (1.5%) to express confidence in Eylea HD vs Vabysmo, size smaller against Roche’s lower beta. Options: if IV falls, buy a 6–9 month call spread (e.g., buy Mar‑2026 ITM call, sell higher strike) to cap premium; hedge with 3‑month puts (cost ≤2–3% portfolio chunk) around major data releases.

Contrarian angles: Consensus may underprice payer pushback and revenue mix dilution from longer dosing intervals—market has bid P/E to 22.2x vs historical ~19x (≈15% premium), so a modest miss could compress multiple and deliver 10–25% downside. Alternatively, Eylea HD adoption could be underappreciated if it reclaims ≥10% market share within 9–12 months, making current optimism still underdone. Watch monthly script share (IQVIA) and next 60–90 day label/payer announcements as binary catalysts that will reveal whether the premium is justified or overpriced.

Key Decisions for Investors

• Initiate a 2–3% long position in REGN on a pullback below $720, target +20–25% in 12 months (~$900), place a hard stop‑loss at 15% below entry to limit downside.
• Enter a relative value pair: long REGN (2% portfolio) vs short RHHBY (1.5%) to express conviction in Eylea HD uptake vs Vabysmo; size small vs Roche due to lower beta and diversify sector exposure.
• Buy a 6–9 month call spread on REGN (buy nearer‑term ITM call, sell higher strike ~20–25% OTM) to participate in upside while capping premium; simultaneously purchase a 3‑month put (protective hedge) around major upcoming script share or earnings dates if protection cost ≤2–3% of position.
• Reduce small‑cap/early‑stage biotech exposure by 2–3% and reallocate to large‑cap biopharma (including REGN, SNY) given defensive cash flows and near‑term catalysts; monitor IQVIA monthly script share and payer coverage notices over next 30–90 days as primary triggers to scale positions up or down.
• If REGN trades to >30% premium over historical P/E (forward P/E >25x) without commensurate upward EPS revisions within 90 days, trim long exposure by 50%—valuation compression risk outweighs near‑term pipeline optionality.